Unlocking the combination to target evasive kidney cancers

Roughly one in four people with kidney cancer have a type that does not respond to targeted therapy drugs, leaving no proven treatment options for those whose tumors have started to...

Multi-cancer early detection is on the horizon

Before cancers become deadly, signs of their presence can show up in escaped strands of DNA and other tell-tale molecules. Technical leaps are making it possible to find these signals in blood,...

First-in-class drug targets resistant ovarian cancer

Cancer researchers have discovered a way to target a pivotal driver of drug resistance in ovarian cancer, one of the top causes of cancer death in women. The experimental compound, called SU056,...

Highlights from the Fifth Early Detection of Cancer Conference

Advancing the early detection of lethal cancers is fundamental to treating patients more effectively. One of the most important factors in cancer survival is diagnosis at an early stage. Screening...

Engineering models of early cancer: Q&A with Carolyn Schutt Ibsen

Carolyn Schutt Ibsen, Ph.D., develops biomaterials that can be controlled remotely and noninvasively using ultrasound. She and her team at OHSU are using these “energy-responsive” materials to...

Knight Cancer Institute signal achievements of 2020

In a year overshadowed by the coronavirus pandemic, the OHSU Knight Cancer Institute's people adapted and accomplished many great things. From basic research, to patient care, to impact in the...

Perturbed tumors reveal their secrets

A trove of freely accessible cancer data helps researchers find new combination treatments. Targeted cancer therapies work by blocking a specific cancer-driving signal, thus limiting harm to healthy...

For veterans with prostate cancer, a new center of excellence in Oregon

VA Portland Health Care System and OHSU are launching a precision oncology center of excellence supported by the Prostate Cancer Foundation. On Veteran's Day, the foundation announced $5 million in...

Beat AML study paves way for precision treatment

Using genetic information to match patients to targeted therapies may improve survival in people with a fast-moving leukemia. Because acute myeloid leukemia is such a fast-moving and deadly cancer,...